Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in patients with ST-elevation myocardial infarction
2021-003340-24Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in acute ST-segment elevation myocardial infarction (STEMI) and myocardial infarction (MI) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Left ventricular ejection fraction at 6 months. Started Jul 2021; status: active.
02
Drugs
rituximab
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)myocardial infarction (MI)
Beyond the preview
Go deeper on 2021-003340-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003340-24.